- Home
- BMA vs DYN Comparison
BMA vs DYN Comparison
Compare BMA & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMA | DYN |
|---|---|---|
| Founded | 1966 | 1984 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.8B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMA | DYN |
|---|---|---|
| Price | $72.84 | $26.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $99.33 | $37.00 |
| AVG Volume (30 Days) | 277.5K | ★ 2.2M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.99% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.30 | $11.92 |
| 52 Week High | $106.15 | $27.31 |
Technical Indicators
Market Signals| Indicator | BMA | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 29.40 | 58.20 |
| Support Level | $71.64 | $16.45 |
| Resistance Level | $95.14 | $26.96 |
| Average True Range (ATR) | 4.13 | 0.96 |
| MACD | -1.25 | -0.15 |
| Stochastic Oscillator | 7.58 | 52.26 |
Price Performance
Historical ComparisonAbout BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.